cGMP-enhancing- and alpha1A/alpha1D-adrenoceptor blockade-derived inhibition of Rho-kinase by KMUP-1 provides optimal prostate relaxation and epithelial cell anti-proliferation efficacy

Prostate. 2007 Sep 15;67(13):1397-410. doi: 10.1002/pros.20634.

Abstract

Background: Soluble guanylyl cyclase (sGC)/cyclic guanosine monophosphate (cGMP)/protein kinase G (PKG) and Rho kinase (ROCK2) pathways are important in the regulation of prostate smooth muscle tone. This study is aimed to examine the relaxation activities of a sGC activator and PDE5A/ROCK2 inhibitor KMUP-1 in rat prostate and associated anti-proliferation activity in human prostatic epithelial cells.

Methods: The action characteristics of KMUP-1 were identified by isometric tension measurement, receptor binding assay, Western blotting and radioimmunoassay in rat prostate. Anti-proliferation activity of KMUP-1 in human prostatic epithelial PZ-HPV-7 cells was identified using flow cytometry and real time QRT-PCR.

Results: KMUP-1 inhibited phenylephrine-induced contractility in a concentration-dependent manner. KMUP-1 possessed potent alpha(1A/)alpha(1D)-adrenoceptor binding inhibition activity, increased cAMP/cGMP levels and increased the expression of sGC, PKG, and PKA protein in rat prostate. Moreover, KMUP-1 inhibited phenylephrine-induced ROCK2 expression. KMUP-1 inhibited cell growth, arrested the cell cycle at G(0)/G(1) phase and increased the expression of p21 in PZ-HPV-7 cells.

Conclusions: These results broaden our knowledge of sGC/cGMP/PKG and ROCK2 regulation on the relaxation and proliferation of prostate, which may help in the design of benign prostate hyperplasia (BPH) therapies that target these signaling pathways. KMUP-1 possesses the potential benefit in the treatment of BPH by its alpha(1A/)alpha(1D)-adrenoceptor blockade, sGC activation, inhibition of PDE5A and ROCK2 and p21 protein enhancement, leading to attenuation of the smooth muscle tone and the proliferation of epithelial PZ-HPV-7 cells. The synergistic contribution of these pathways by KMUP-1 may benefit BPH patients with lower urinary tract symptoms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors
  • Adrenergic alpha-Antagonists / pharmacology*
  • Animals
  • Blotting, Western
  • Cell Proliferation / drug effects
  • Cyclic AMP / metabolism
  • Cyclic GMP / metabolism*
  • Cyclic GMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic GMP-Dependent Protein Kinases / metabolism
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Drug Synergism
  • Epithelial Cells / cytology
  • Epithelial Cells / drug effects
  • Humans
  • In Vitro Techniques
  • Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Male
  • Muscle Contraction / drug effects
  • Muscle, Smooth / drug effects
  • Piperazines / pharmacology
  • Piperidines / pharmacology*
  • Prostate / drug effects*
  • Prostate / metabolism
  • Prostate / physiology
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Protein Serine-Threonine Kinases / metabolism
  • Purines / pharmacology
  • Rats
  • Rats, Wistar
  • Receptors, Adrenergic, alpha / metabolism
  • Sildenafil Citrate
  • Sulfonamides / pharmacology
  • Sulfones / pharmacology
  • Tamsulosin
  • Xanthines / pharmacology*
  • rho-Associated Kinases

Substances

  • Adrenergic alpha-Antagonists
  • Intracellular Signaling Peptides and Proteins
  • Piperazines
  • Piperidines
  • Purines
  • Receptors, Adrenergic, alpha
  • Sulfonamides
  • Sulfones
  • Xanthines
  • KMUP 1
  • Sildenafil Citrate
  • Cyclic AMP
  • Protein Serine-Threonine Kinases
  • ROCK2 protein, human
  • rho-Associated Kinases
  • Cyclic GMP-Dependent Protein Kinases
  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • PDE5A protein, human
  • Pde5a protein, rat
  • Tamsulosin
  • Cyclic GMP